Pelvital Secures $5M to Revolutionize Women's Health

Pelvital USA, Inc., a trailblazer in women's health, has closed a $5M seed-plus funding round to propel their groundbreaking treatment for stress urinary incontinence (SUI). Led by Boomerang Ventures, this investment will turbocharge the commercialization of Flyte, a game-changing solution for women battling SUI. Flyte, an FDA-cleared treatment, offers a non-invasive option to strengthen pelvic floor muscles with just five minutes a day for six weeks. Clinical trials have shown Flyte's efficacy, with 71% of participants achieving dry or near dry status. Pelvital's CEO, Lydia Zeller, emphasizes the importance of this funding in advancing women's pelvic health solutions and expanding access to Flyte. With new investors on board, including Pier 70 Ventures and Life Science Angels, Pelvital is poised to revolutionize women's health with Flyte.